{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:59:08Z","timestamp":1791248348365,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,7,30]],"date-time":"2009-07-30T00:00:00Z","timestamp":1248912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Autoantibodies such as rheumatoid factor (RF) and anti\u2013citrullinated protein autoantibodies (ACPAs) determined by testing with second\u2010generation anti\u2013cyclic citrullinated peptide (anti\u2013CCP\u20102) are frequently measured in clinical practice because of their association with disease outcome in undifferentiated arthritis (UA) and rheumatoid arthritis (RA). Recently, 2 new ACPA tests were developed: third\u2010generation anti\u2010CCP (anti\u2013CCP\u20103) and anti\u2013modified citrullinated vimentin (anti\u2010MCV) autoantibody tests. To facilitate the decision on which autoantibody to test in daily practice, this study evaluated the capability of these autoantibodies and combinations of them to predict 3 outcome measures: progression from UA to RA, the rate of joint destruction in RA, and the chance of achieving sustained disease\u2010modifying antirheumatic drug (DMARD)\u2013free remission in RA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with UA (n = 625) were studied for whether UA progressed to RA after 1 year. Patients with RA (n = 687) were studied for whether sustained DMARD\u2010free remission was achieved and for the rate of joint destruction during a median followup of 5 years. Positive predictive values (PPVs) for RA development and for associations with the disease course in RA were compared between single tests (anti\u2013CCP\u20102, anti\u2013CCP\u20103, anti\u2010MCV, and RF) and between combinations of these tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the single tests performed in patients with UA, anti\u2013CCP\u20102 tended to have the highest PPV for RA development (67.1%), but the 95% confidence intervals of the other tests overlapped. Among the single tests in patients with RA, all 4 tests showed comparable associations with the rate of joint destruction and with the achievement of remission. In both ACPA\u2010positive and ACPA\u2010negative RA, the presence of RF was not associated with more joint destruction. For all outcome measures, performing combinations of 2 or 3 autoantibody tests did not increase the predictive accuracy compared with performing a single test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>For clinical practice, a single autoantibody test is sufficient for risk estimation in UA and RA.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.24716","type":"journal-article","created":{"date-parts":[[2009,7,30]],"date-time":"2009-07-30T15:15:42Z","timestamp":1248966942000},"page":"2232-2241","source":"Crossref","is-referenced-by-count":135,"title":["Value of anti\u2013modified citrullinated vimentin and third\u2010generation anti\u2013cyclic citrullinated peptide compared with second\u2010generation anti\u2013cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis"],"prefix":"10.1002","volume":"60","author":[{"given":"Michael P. M.","family":"van der Linden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Ioan\u2010Facsinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. W. Nivine","family":"Levarht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrie","family":"Stoeken\u2010Rijsbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W. J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 E. M.","family":"Toes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette H. M.","family":"van der Helm\u2010van Mil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,30]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199912)42:12<2499::AID-ANR1>3.0.CO;2-R"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2008"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0614-8"},{"key":"e_1_2_7_7_2","first-page":"1658","article-title":"Clinical evaluation of anti\u2010mutated citrullinated vimentin by ELISA in rheumatoid arthritis","volume":"34","author":"Soos L","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.017574"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22817"},{"key":"e_1_2_7_10_2","article-title":"A comparative study of IgG second\u2010 and third\u2010generation anti\u2010cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third\u2010generation CCP ELISA for the diagnosis of rheumatoid arthritis","author":"Enriconi dos Anjos LM","year":"2008","journal-title":"Clin Rheumatol"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11223"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20018"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2007.08.002"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1149"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-007-8016-3"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20044"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0558-5"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel237"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2362"},{"key":"e_1_2_7_20_2","first-page":"1002","article-title":"Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides","volume":"35","author":"Innala L","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23188"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1983"},{"issue":"5","key":"e_1_2_7_23_2","first-page":"S100","article-title":"The Leiden Early Arthritis Clinic","volume":"21","author":"Van Aken J","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10151"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22380"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.rheumatology.a031496"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.12.1213"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24661"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.5.427"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22279"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23763"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.24716","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.24716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T13:37:12Z","timestamp":1696772232000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.24716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,30]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1002\/art.24716"],"URL":"https:\/\/doi.org\/10.1002\/art.24716","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,30]]}}}